Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue: Implications for durable risk reduction

David Euhus, Dawei Bu, Xian Jin Xie, Venetia Sarode, Raheela Ashfaq, Kelly Hunt, Weiya Xia, Joyce O'Shaughnessy, Michael Grant, Banu Arun, William Dooley, Alexander Miller, David Flockhart, Cheryl Lewis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate new mechanisms of breast carcinogenesis, suggest novel chemoprevention targets, and provide relevant early response biomarkers for phase II prevention trials. Seventy-three women at increased risk for breast cancer were randomized to tamoxifen (20 mg daily) or placebo for 3 months. Blood and breast tissue samples were collected at baseline and posttreatment. Sixty-nine women completed all study activities (37 tamoxifen and 32 placebo). The selected biomarkers focused on estradiol and IGFs in the blood; DNA methylation and cytology in random periareolar fine-needle aspirates; and tissue morphometry, proliferation, apoptosis, and gene expression (microarray and reverse transcriptase PCR) in the tissue core samples. Tamoxifen downregulated Ets oncogene transcription factor family members ETV4 and ETV5 and reduced breast epithelial cell proliferation independent of CYP2D6 genotypes or effects on estradiol, ESR1, or IGFs. Reduction in proliferation was correlated with downregulation of ETV4 and DNAJC12. Tamoxifen reduced the expression of ETV4- and ETV5-regulated genes implicated in epithelial-stromal interaction and tissue remodeling. Three months of tamoxifen did not affect breast tissue composition, cytologic atypia, preneoplasia, or apoptosis. A plausible mechanism for the chemopreventive effects of tamoxifen is restriction of lobular expansion into stroma through downregulation of ETV4 and ETV5. The human equivalent of murine multipotential progenitor cap cells of terminal end buds may be the primary target.

Original languageEnglish
Pages (from-to)1852-1862
Number of pages11
JournalCancer Prevention Research
Volume4
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Tamoxifen
Risk Reduction Behavior
Oncogenes
Breast
Down-Regulation
Estradiol
Biomarkers
Proto-Oncogene Proteins c-ets
Placebos
Apoptosis
Breast Neoplasms
Cytochrome P-450 CYP2D6
Chemoprevention
DNA Methylation
Reverse Transcriptase Polymerase Chain Reaction
Needles
Cell Biology
Carcinogenesis
Stem Cells
Epithelial Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue : Implications for durable risk reduction. / Euhus, David; Bu, Dawei; Xie, Xian Jin; Sarode, Venetia; Ashfaq, Raheela; Hunt, Kelly; Xia, Weiya; O'Shaughnessy, Joyce; Grant, Michael; Arun, Banu; Dooley, William; Miller, Alexander; Flockhart, David; Lewis, Cheryl.

In: Cancer Prevention Research, Vol. 4, No. 11, 11.2011, p. 1852-1862.

Research output: Contribution to journalArticle

Euhus, D, Bu, D, Xie, XJ, Sarode, V, Ashfaq, R, Hunt, K, Xia, W, O'Shaughnessy, J, Grant, M, Arun, B, Dooley, W, Miller, A, Flockhart, D & Lewis, C 2011, 'Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue: Implications for durable risk reduction', Cancer Prevention Research, vol. 4, no. 11, pp. 1852-1862. https://doi.org/10.1158/1940-6207.CAPR-11-0186
Euhus, David ; Bu, Dawei ; Xie, Xian Jin ; Sarode, Venetia ; Ashfaq, Raheela ; Hunt, Kelly ; Xia, Weiya ; O'Shaughnessy, Joyce ; Grant, Michael ; Arun, Banu ; Dooley, William ; Miller, Alexander ; Flockhart, David ; Lewis, Cheryl. / Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue : Implications for durable risk reduction. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 11. pp. 1852-1862.
@article{4472032a096f4a6eb5623d4407439837,
title = "Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue: Implications for durable risk reduction",
abstract = "Five years of tamoxifen reduces breast cancer risk by nearly 50{\%} but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate new mechanisms of breast carcinogenesis, suggest novel chemoprevention targets, and provide relevant early response biomarkers for phase II prevention trials. Seventy-three women at increased risk for breast cancer were randomized to tamoxifen (20 mg daily) or placebo for 3 months. Blood and breast tissue samples were collected at baseline and posttreatment. Sixty-nine women completed all study activities (37 tamoxifen and 32 placebo). The selected biomarkers focused on estradiol and IGFs in the blood; DNA methylation and cytology in random periareolar fine-needle aspirates; and tissue morphometry, proliferation, apoptosis, and gene expression (microarray and reverse transcriptase PCR) in the tissue core samples. Tamoxifen downregulated Ets oncogene transcription factor family members ETV4 and ETV5 and reduced breast epithelial cell proliferation independent of CYP2D6 genotypes or effects on estradiol, ESR1, or IGFs. Reduction in proliferation was correlated with downregulation of ETV4 and DNAJC12. Tamoxifen reduced the expression of ETV4- and ETV5-regulated genes implicated in epithelial-stromal interaction and tissue remodeling. Three months of tamoxifen did not affect breast tissue composition, cytologic atypia, preneoplasia, or apoptosis. A plausible mechanism for the chemopreventive effects of tamoxifen is restriction of lobular expansion into stroma through downregulation of ETV4 and ETV5. The human equivalent of murine multipotential progenitor cap cells of terminal end buds may be the primary target.",
author = "David Euhus and Dawei Bu and Xie, {Xian Jin} and Venetia Sarode and Raheela Ashfaq and Kelly Hunt and Weiya Xia and Joyce O'Shaughnessy and Michael Grant and Banu Arun and William Dooley and Alexander Miller and David Flockhart and Cheryl Lewis",
year = "2011",
month = "11",
doi = "10.1158/1940-6207.CAPR-11-0186",
language = "English",
volume = "4",
pages = "1852--1862",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue

T2 - Implications for durable risk reduction

AU - Euhus, David

AU - Bu, Dawei

AU - Xie, Xian Jin

AU - Sarode, Venetia

AU - Ashfaq, Raheela

AU - Hunt, Kelly

AU - Xia, Weiya

AU - O'Shaughnessy, Joyce

AU - Grant, Michael

AU - Arun, Banu

AU - Dooley, William

AU - Miller, Alexander

AU - Flockhart, David

AU - Lewis, Cheryl

PY - 2011/11

Y1 - 2011/11

N2 - Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate new mechanisms of breast carcinogenesis, suggest novel chemoprevention targets, and provide relevant early response biomarkers for phase II prevention trials. Seventy-three women at increased risk for breast cancer were randomized to tamoxifen (20 mg daily) or placebo for 3 months. Blood and breast tissue samples were collected at baseline and posttreatment. Sixty-nine women completed all study activities (37 tamoxifen and 32 placebo). The selected biomarkers focused on estradiol and IGFs in the blood; DNA methylation and cytology in random periareolar fine-needle aspirates; and tissue morphometry, proliferation, apoptosis, and gene expression (microarray and reverse transcriptase PCR) in the tissue core samples. Tamoxifen downregulated Ets oncogene transcription factor family members ETV4 and ETV5 and reduced breast epithelial cell proliferation independent of CYP2D6 genotypes or effects on estradiol, ESR1, or IGFs. Reduction in proliferation was correlated with downregulation of ETV4 and DNAJC12. Tamoxifen reduced the expression of ETV4- and ETV5-regulated genes implicated in epithelial-stromal interaction and tissue remodeling. Three months of tamoxifen did not affect breast tissue composition, cytologic atypia, preneoplasia, or apoptosis. A plausible mechanism for the chemopreventive effects of tamoxifen is restriction of lobular expansion into stroma through downregulation of ETV4 and ETV5. The human equivalent of murine multipotential progenitor cap cells of terminal end buds may be the primary target.

AB - Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate new mechanisms of breast carcinogenesis, suggest novel chemoprevention targets, and provide relevant early response biomarkers for phase II prevention trials. Seventy-three women at increased risk for breast cancer were randomized to tamoxifen (20 mg daily) or placebo for 3 months. Blood and breast tissue samples were collected at baseline and posttreatment. Sixty-nine women completed all study activities (37 tamoxifen and 32 placebo). The selected biomarkers focused on estradiol and IGFs in the blood; DNA methylation and cytology in random periareolar fine-needle aspirates; and tissue morphometry, proliferation, apoptosis, and gene expression (microarray and reverse transcriptase PCR) in the tissue core samples. Tamoxifen downregulated Ets oncogene transcription factor family members ETV4 and ETV5 and reduced breast epithelial cell proliferation independent of CYP2D6 genotypes or effects on estradiol, ESR1, or IGFs. Reduction in proliferation was correlated with downregulation of ETV4 and DNAJC12. Tamoxifen reduced the expression of ETV4- and ETV5-regulated genes implicated in epithelial-stromal interaction and tissue remodeling. Three months of tamoxifen did not affect breast tissue composition, cytologic atypia, preneoplasia, or apoptosis. A plausible mechanism for the chemopreventive effects of tamoxifen is restriction of lobular expansion into stroma through downregulation of ETV4 and ETV5. The human equivalent of murine multipotential progenitor cap cells of terminal end buds may be the primary target.

UR - http://www.scopus.com/inward/record.url?scp=81555195404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81555195404&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-11-0186

DO - 10.1158/1940-6207.CAPR-11-0186

M3 - Article

C2 - 21778330

AN - SCOPUS:81555195404

VL - 4

SP - 1852

EP - 1862

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 11

ER -